These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 21671822)

  • 1. The correlation between zinc and insulin-like growth factor 1 (IGF-1), its binding protein (IGFBP-3) and prostate-specific antigen (PSA) in prostate cancer.
    Daragó A; Sapota A; Matych J; Nasiadek M; Skrzypińska-Gawrysiak M; Kilanowicz A
    Clin Chem Lab Med; 2011 Oct; 49(10):1699-705. PubMed ID: 21671822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum insulin-like growth factor I/free prostate specific antigen (IGF-I/fPSA) ratio enhances prostate cancer detection in men with total PSA 4.0-10.0 ng/ml.
    Zhigang Z; Jieming L; Su L; Wenlu S
    J Surg Oncol; 2007 Jul; 96(1):54-61. PubMed ID: 17345593
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship of insulin-like growth factor (IGF) binding protein-3 (IGFBP-3) gene polymorphism with the susceptibility to development of prostate cancer and influence on serum levels of IGF-I, and IGFBP-3.
    Safarinejad MR; Shafiei N; Safarinejad S
    Growth Horm IGF Res; 2011 Jun; 21(3):146-54. PubMed ID: 21536469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and prostate cancer: correlation with Gleason score.
    Correa LL; Neto LV; Lima GA; Gabrich R; Miranda LC; Gadelha MR
    Int Braz J Urol; 2015; 41(1):110-5. PubMed ID: 25928516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
    Khosravi J; Diamandi A; Mistry J; Scorilas A
    J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer.
    Miyata Y; Sakai H; Hayashi T; Kanetake H
    Prostate; 2003 Feb; 54(2):125-32. PubMed ID: 12497585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluating serum insulin-like growth factor 1 and insulin-like growth factor binding protein 3 as markers in prostate cancer diagnosis.
    Rainato G; Fabricio AS; Zancan M; Peloso L; Dittadi R; Barichello M; Fandella A; Scattoni V; Gion M
    Int J Biol Markers; 2016 Jul; 31(3):e317-23. PubMed ID: 26954072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia.
    Aksoy Y; Aksoy H; Bakan E; Atmaca AF; Akçay F
    Urol Int; 2004; 72(1):62-5. PubMed ID: 14730168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum insulin-like growth factor-I levels and prostatic intraepithelial neoplasia: a clue to the relationship between IGF-I physiology and prostate cancer risk.
    Nam RK; Trachtenberg J; Jewett MA; Toi A; Evans A; Emami M; Narod SA; Pollak M
    Cancer Epidemiol Biomarkers Prev; 2005 May; 14(5):1270-3. PubMed ID: 15894684
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Measurement of insulin-like growth factor axis does not enhance specificity of PSA-based prostate cancer screening.
    Oliver SE; Holly J; Peters TJ; Donovan J; Persad R; Gillatt D; Pearce A; Hamdy FC; Neal DE; Gunnell D
    Urology; 2004 Aug; 64(2):317-22. PubMed ID: 15302487
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
    Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
    Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
    Finne P; Auvinen A; Koistinen H; Zhang WM; Määttänen L; Rannikko S; Tammela T; Seppälä M; Hakama M; Stenman UH
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2744-7. PubMed ID: 10946875
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ratios of IGF-I, IGF binding protein-3, and prostate-specific antigen in prostate cancer detection.
    Stattin P; Stenman UH; Riboli E; Hallmans G; Kaaks R
    J Clin Endocrinol Metab; 2001 Dec; 86(12):5745-8. PubMed ID: 11739433
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma insulin-like growth factor-1 and binding protein-3 and subsequent risk of prostate cancer in the PSA era.
    Platz EA; Pollak MN; Leitzmann MF; Stampfer MJ; Willett WC; Giovannucci E
    Cancer Causes Control; 2005 Apr; 16(3):255-62. PubMed ID: 15947877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.
    Stattin P; Bylund A; Rinaldi S; Biessy C; Déchaud H; Stenman UH; Egevad L; Riboli E; Hallmans G; Kaaks R
    J Natl Cancer Inst; 2000 Dec; 92(23):1910-7. PubMed ID: 11106682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
    Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
    J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elevated insulin and reduced insulin like growth factor binding protein-3/prostate specific antigen ratio with increase in prostate size in Benign Prostatic Hyperplasia.
    Sreenivasulu K; Nandeesha H; Dorairajan LN; Rajappa M; Vinayagam V
    Clin Chim Acta; 2017 Jun; 469():37-41. PubMed ID: 28300542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Changes of serum total PSA and free PSA in patients with prostate carcinoma and benign prostate hyperplasia].
    Gao ZW; Liu G; Sheng BW
    Ai Zheng; 2004 Jun; 23(6):701-3. PubMed ID: 15191675
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ; Baxter RC
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):333-42. PubMed ID: 9156044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are plasma insulin-like growth factor I (IGF-I) and IGF-binding protein 3 (IGFBP-3) useful markers of prostate cancer?
    Lopez JB; Sahabudin RM; Chin LP
    Int J Biol Markers; 2004; 19(2):164-7. PubMed ID: 15255551
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.